Literature DB >> 19763148

Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology.

Bali Pulendran1.   

Abstract

Despite their great success, we understand little about how effective vaccines stimulate protective immune responses. Two recent developments promise to yield such understanding: the appreciation of the crucial role of the innate immune system in sensing microorganisms and tuning immune responses, and advances in systems biology. Here I review how these developments are yielding insights into the mechanism of action of the yellow fever vaccine, one of the most successful vaccines ever developed, and the broader implications for vaccinology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19763148     DOI: 10.1038/nri2629

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  46 in total

1.  Concurrent and consecutive infection and immunisation with yellow fever and UGMP-359 viruses.

Authors:  T S David-West
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

Review 2.  Variegation of the immune response with dendritic cells and pathogen recognition receptors.

Authors:  Bali Pulendran
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

Review 3.  Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?

Authors:  Alan D T Barrett; Dirk E Teuwen
Journal:  Curr Opin Immunol       Date:  2009-06-10       Impact factor: 7.486

4.  The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I.

Authors:  Simon Rothenfusser; Nadege Goutagny; Gary DiPerna; Mei Gong; Brian G Monks; Annett Schoenemeyer; Masahiro Yamamoto; Shizuo Akira; Katherine A Fitzgerald
Journal:  J Immunol       Date:  2005-10-15       Impact factor: 5.422

5.  Dengue virus induces expression of CXC chemokine ligand 10/IFN-gamma-inducible protein 10, which competitively inhibits viral binding to cell surface heparan sulfate.

Authors:  Jia-Perng Chen; Hsin-Lin Lu; Szu-Liang Lai; Gabriele S Campanella; Jui-Ming Sung; Mei-Yi Lu; Betty A Wu-Hsieh; Yi-Ling Lin; Thomas E Lane; Andrew D Luster; Fang Liao
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

6.  A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.

Authors:  F Guirakhoo; Z Zhang; G Myers; B W Johnson; K Pugachev; R Nichols; N Brown; I Levenbook; K Draper; S Cyrek; J Lang; C Fournier; B Barrere; S Delagrave; T P Monath
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes.

Authors:  Bali Pulendran; Joseph Miller; Troy D Querec; Rama Akondy; Nelson Moseley; Oscar Laur; John Glidewell; Nathan Monson; Tuofu Zhu; Haiying Zhu; Sylvija Staprans; David Lee; Margo A Brinton; Andrey A Perelygin; Claudia Vellozzi; Philip Brachman; Susan Lalor; Dirk Teuwen; Rachel B Eidex; Marty Cetron; Frances Priddy; Carlos del Rio; John Altman; Rafi Ahmed
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

8.  A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus.

Authors:  Damien Chaussabel; Charles Quinn; Jing Shen; Pinakeen Patel; Casey Glaser; Nicole Baldwin; Dorothee Stichweh; Derek Blankenship; Lei Li; Indira Munagala; Lynda Bennett; Florence Allantaz; Asuncion Mejias; Monica Ardura; Ellen Kaizer; Laurence Monnet; Windy Allman; Henry Randall; Diane Johnson; Aimee Lanier; Marilynn Punaro; Knut M Wittkowski; Perrin White; Joseph Fay; Goran Klintmalm; Octavio Ramilo; A Karolina Palucka; Jacques Banchereau; Virginia Pascual
Journal:  Immunity       Date:  2008-07-18       Impact factor: 31.745

9.  Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway.

Authors:  Weiping Cao; Santhakumar Manicassamy; Hua Tang; Sudhir Pai Kasturi; Ali Pirani; Niren Murthy; Bali Pulendran
Journal:  Nat Immunol       Date:  2008-08-31       Impact factor: 25.606

10.  Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease.

Authors:  Jon L Belsher; Peter Gay; Margo Brinton; Joseph DellaValla; Robert Ridenour; Robert Lanciotti; Andrey Perelygin; Sherif Zaki; Christopher Paddock; Troy Querec; Tuofu Zhu; Bali Pulendran; Rachel B Eidex; Edward Hayes
Journal:  Vaccine       Date:  2007-09-18       Impact factor: 3.641

View more
  128 in total

1.  The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise.

Authors: 
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

Review 2.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 3.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

4.  Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation.

Authors:  Janine K Tom; Rock J Mancini; Aaron P Esser-Kahn
Journal:  Chem Commun (Camb)       Date:  2013-10-25       Impact factor: 6.222

Review 5.  Systems immunology: just getting started.

Authors:  Mark M Davis; Cristina M Tato; David Furman
Journal:  Nat Immunol       Date:  2017-06-20       Impact factor: 25.606

Review 6.  Some unmet challenges in the immunology of viral infections.

Authors:  Barry T Rouse; Aron E Lukacher
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

Review 7.  How innate immune mechanisms contribute to antibody-enhanced viral infections.

Authors:  Sukathida Ubol; Scott B Halstead
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

Review 8.  The potential of the microbiota to influence vaccine responses.

Authors:  David J Lynn; Bali Pulendran
Journal:  J Leukoc Biol       Date:  2017-12-28       Impact factor: 4.962

Review 9.  Modeling HIV vaccine trials of the future.

Authors:  Peter B Gilbert; Ying Huang; Holly E Janes
Journal:  Curr Opin HIV AIDS       Date:  2016-11       Impact factor: 4.283

Review 10.  The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; V Shane Pankratz; Richard B Kennedy; Robert M Jacobson; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.